Jia L. Yan
Xin Hua Street No. 5, Hui Min District
Hohhot, China
Hohhot, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma.
Journal: Biochemical pharmacology
Published: September 05, 2025
Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism.
Journal: Journal of translational medicine
Published: August 06, 2025
Norcantharidin inhibits TOP2A expression via H3K27me3 mediated epigenetic regulation to alleviate the progression of hepatocellular carcinoma.
Journal: Frontiers in pharmacology
Published: December 07, 2024
Association of frailty index with the risk for cardiovascular disease in adults
Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Published: December 04, 2024
BRD1 deficiency affects SREBF1-related lipid metabolism through regulating H3K9ac/H3K9me3 transition to inhibit HCC progression.
Journal: Cell death & disease
Published: June 19, 2024
Identification of RFC4 as a potential biomarker for pan-cancer involving prognosis, tumour immune microenvironment and drugs.
Journal: Journal of cellular and molecular medicine
Published: February 04, 2024
PRMT1 Integrates Immune Microenvironment and Fatty Acid Metabolism Response in Progression of Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: October 26, 2023
Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Journal: BMC cancer
Published: February 24, 2023
WHSC1 is involved in DNA damage, cellular senescence and immune response in hepatocellular carcinoma progression.
Journal: Journal of cellular and molecular medicine
Published: February 22, 2023
Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response.
Journal: BMC complementary medicine and therapies
Published: November 23, 2022
SPATS2 is correlated with cell cycle progression and immune cells infiltration in hepatocellular carcinoma.
Journal: BMC gastroenterology
Published: September 27, 2022
Last Updated: 09/26/2026